Tarsus Pharmaceuticals financials
$76.69−0.16%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $173.9M | $162.1M | $151.7M | $118.7M | $102.7M | $78.3M | $66.4M | $48.1M | $40.8M | $27.6M | $13.1M | $1.9M |
| Gross profit | $161.8M | $152.7M | $140.7M | $110.4M | $96.4M | $73.1M | $61.5M | $44.9M | $37.8M | $26.0M | $11.9M | $1.5M |
| Gross margin | 93.0% | 94.2% | 92.8% | 93.0% | 93.9% | 93.3% | 92.6% | 93.3% | 92.6% | 94.0% | 90.7% | 79.9% |
| Operating income | -$19.9M | -$6.1M | -$8.0M | -$14.5M | -$22.2M | -$26.3M | -$24.4M | -$25.2M | -$33.3M | -$37.7M | -$44.5M | -$40.9M |
| Net income | -$18.6M | -$7.6M | -$8.2M | -$12.6M | -$20.3M | -$25.2M | -$22.9M | -$23.4M | -$33.3M | -$35.7M | -$41.9M | -$39.1M |
| Net margin | −10.7% | −4.7% | −5.4% | −10.6% | −19.8% | −32.2% | −34.5% | −48.7% | −81.6% | −129.4% | −320.4% | −2092.4% |
| Diluted EPS | $-0.43 | $-0.16 | $-0.19 | $-0.30 | $-0.48 | $-0.64 | $-0.59 | $-0.61 | $-0.88 | $-1.01 | $-1.26 | $-1.28 |
| EBITDA | -$18.1M | -$6.5M | -$13.0M | -$14.1M | -$20.4M | -$27.1M | -$28.2M | -$24.9M | -$33.1M | -$37.4M | -$44.5M | -$40.7M |
| Operating cash flow | $61.2M | -$24.7M | $19.3M | $18.3M | -$29.4M | -$20.7M | -$22.2M | -$8.7M | -$14.4M | -$37.8M | -$39.3M | -$32.4M |
| Free cash flow | $57.2M | -$30.5M | $13.0M | $16.3M | -$30.4M | -$21.2M | -$22.3M | -$8.9M | -$15.4M | -$38.0M | -$39.3M | -$32.7M |
| Diluted shares | 43.4M | 43.0M | 42.8M | 42.6M | 42.4M | 39.3M | 38.9M | 38.4M | 37.8M | 35.3M | 33.4M | 30.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $204.6M | $102.2M | $183.6M | $112.7M | $96.6M | $175.8M |
| Short-term investments | $245.1M | $286.5M | $233.6M | $289.1M | $284.5M | $232.1M |
| Total debt | $72.8M | $72.6M | $72.4M | $72.3M | $72.1M | $72.0M |
| Total assets | $611.1M | $581.1M | $562.2M | $534.6M | $495.0M | $500.8M |
| Total liabilities | $264.4M | $232.2M | $218.7M | $199.5M | $162.4M | $158.3M |
| Shareholders' equity | $346.7M | $349.0M | $343.4M | $335.1M | $332.6M | $342.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology